FLT3 and acute myeloid leukemia: Recent basic research findings indicate that the synergism of T-cells and sorafenib may metabolically reprogram AML-reactive T-cells, providing potential to contribute to immune-mediated curative treatment of FLT3-ITD mutated AML relapse (44).